

# Daiana Ibarretxe

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5001374/daiana-ibarretxe-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

434  
citations

13  
h-index

20  
g-index

37  
ext. papers

636  
ext. citations

3.3  
avg. IF

3.48  
L-index

#	Paper	IF	Citations
36	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 775677	5.7	0
35	DNA methylation pattern of hypertriglyceridemic subjects. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2021</b> , 34, 27-27	1.4	0
34	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk.. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 781789	4.6	0
33	Magnetic resonance-assessed lipoprotein profile. The time has come for its clinical use. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2021</b> , 75, 5-5	0.7	
32	Long-term exposure to PM above WHO guidelines exacerbates COVID-19 severity and mortality. <i>Environment International</i> , <b>2021</b> , 158, 106930	12.9	7
31	Low HDL and high triglycerides predict COVID-19 severity. <i>Scientific Reports</i> , <b>2021</b> , 11, 7217	4.9	40
30	Triglyceride metabolism and classification of hypertriglyceridemias. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2021</b> , 33 Suppl 2, 1-6	1.4	1
29	Dietary intake and lipid levels in Norwegian and Spanish children with familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 1299-1307	4.5	1
28	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2021</b> , 33, 138-147	1.4	0
27	Serum glycoproteins A and B assessed by H-NMR in familial hypercholesterolemia. <i>Atherosclerosis</i> , <b>2021</b> , 330, 1-7	3.1	2
26	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy. <i>Current Cardiology Reports</i> , <b>2020</b> , 22, 66	4.2	6
25	Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13345	4.6	5
24	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2020</b> , 32, 49-58	1.4	1
23	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale <sup>®</sup> ). <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2020</b> , 32, 219-229	1.4	2
22	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , <b>2019</b> , 287, 89-92	3.1	20
21	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. <i>Advances in Therapy</i> , <b>2019</b> , 36, 1786-1811	4.1	22
20	Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti-β2-Glycoprotein I and Small Dense High-Density Lipoprotein Particles. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 116-125	4.7	7

19	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	21
18	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	17
17	Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2018</b> , 30, 170-178	1.4	7
16	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 292-299.e3	4.9	33
15	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. <i>Atherosclerosis</i> , <b>2018</b> , 270, 117-122	3.1	7
14	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 211-218	4.9	10
13	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 1482-1492.e3	4.9	14
12	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 1452-1462	4.9	7
11	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project. <i>Atherosclerosis</i> , <b>2018</b> , 278, 210-216	3.1	12
10	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. <i>Atherosclerosis</i> , <b>2017</b> , 262, 107-112	3.1	19
9	Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. <i>Journal of Endocrinology</i> , <b>2017</b> , 233, R173-R184	4.7	58
8	Familial hypercholesterolemia in childhood and adolescents: A hidden reality. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2017</b> , 29, 129-140	1.4	7
7	Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 1280-1283	4.9	5
6	Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 92-100.e1	4.9	22
5	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 107	8.7	24
4	Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 330-8.e2	4.9	7
3	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2016</b> , 28, 71-8	1.4	26
2	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2014</b> , 26, 58-65	1.4	4

- 1 Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. *Journal of Nutritional Biochemistry*, **2014**, 25, 642-6

6.3 19